SANOFI (SAN.PA) 101 +1 (+1%)
101 +1 (+1%)
FR0000120578 - Common Stock
Fundamental Rating
Taking everything into account, SAN scores 4 out of 10 in our fundamental rating. SAN was compared to 22 industry peers in the Pharmaceuticals industry. SAN has a medium profitability rating, but doesn't score so well on its financial health evaluation. SAN is quite expensive at the moment. It does show a decent growth rate.
Profitability
Profitability Rating
SAN has a Profit Margin of 18.16%. This is better than the industry average of 17.48%.
The Piotroski-F score of SAN is 7.00. This is a strong score and indicates good health and profitability for SAN.
SAN has a Return On Assets of 9.83%. This is comparable to the industry average of 9.83%.
SAN's Return On Equity of 16.66% is in line with the rest of the industry. The industry average Return On Equity is 16.66%.
VS Industry
ROA (9.83%) VS Industry: 53% outperformed.
0.12
38.37
ROE (16.66%) VS Industry: 53% outperformed.
0.18
141.12
Profit Margin (18.16%) VS Industry: 61% outperformed.
0.21
51.00
Valuation
Valuation Rating
With a Price/Earnings Ratio of 12.24, SAN is valued correctly.
Compared to an average industry Price/Earning Ratio of 16.84, SAN is valued in line with its industry peers.
The Forward Price/Earnings Ratio of 12.16 indicates a correct valuation of SAN.
With a price book ratio of 3.37, SAN is valued correctly.
The high PEG Ratio, which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
Compared to an average industry price book ratio of 2.84, SAN is valued more expensive than its industry peers.
When comparing the Enterprise Value to EBITDA ratio of SAN to the average industry ratio of 9.42, SAN is valued more expensive than its industry peers.
VS Industry
Price/Earnings (12.24) VS Industry: 53% outperformed.
501.25
6.05
Price/Book (3.37) VS Industry: 35% outperformed.
29.03
0.35
Enterprise Value/ EBITDA (11.4) VS Industry: 38% outperformed.
32.48
1.72
Growth
Growth Rating
SAN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 25.95%, which is quite impressive.
SAN shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 16.45%.
Measured over the past 5 years, SAN shows a small growth in Earnings Per Share. The EPS has been growing by 8.29% on average per year.
Based on estimates for the next 5 years, SAN will show a small growth in Earnings Per Share. The EPS will grow by 7.29% on average per year.
When comparing the EPS growth rate of the last years to the growth rate of the upcoming 5 years, we see that the growth is stable.
Measured over the past 5 years, SAN shows a small growth in Revenue. The Revenue has been growing by 4.62% on average per year.
The Revenue is expected to grow by 4.95% on average over the next 5 years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming 5 years, we see that the growth is stable.
| Past | Future | ||||||
|---|---|---|---|---|---|---|---|
| 5Y | 3Y | 1Y | 1Y | 2Y | 3Y | 5Y | |
| EPS | 8.29% | 11.26% | 25.95% | 0.67% | 4.6% | 6.55% | 7.29% |
| Revenue | 4.62% | 6.45% | 16.45% | 2% | 3.69% | 4.23% | 4.95% |
Health
Health Rating
The Piotroski-F score of SAN is 7.00. This is a strong score and indicates good health and profitability for SAN.
A Current Ratio of 1.42 indicates that SAN should not have too much problems paying its short term obligations.
The Current Ratio is in line with the industry averages, which is at 1.42.
SAN has a Quick Ratio of 1.05. This is a normal value and indicates that SAN is financially healthy and should not expect problems in meeting its short term obligations.
The Quick Ratio is in line with the industry averages, which is at 1.05.
The Debt to Equity ratio of SAN is in line with the industry averages.
VS Industry
Debt/Equity (0.23) VS Industry: 58% outperformed.
5.23
0.00
Quick Ratio (1.05) VS Industry: 52% outperformed.
0.58
8.84
Current Ratio (1.42) VS Industry: 52% outperformed.
0.86
8.84
Dividend
Dividend Rating
Compared to an average S&P500 Dividend Yield of 2.60, SAN pays a bit more dividend than the S&P500 average.
33.46% of the earnings are spent on dividend by SAN. This is a low number and sustainable payout ratio.
SAN has a Yearly Dividend Yield of 3.69%.
Compared to an average industry Dividend Yield of 3.69, SAN has a dividend in line with its industry peers.
The dividend of SAN has a limited annual growth rate of 4.16%.
The dividend of SAN is growing around the same rate as the earnings are growing. If this keeps up the dividend growth is sustainable.
VS Industry
Dividend Yield (3.69%) VS Industry: 55% outperformed.
1.14
6.42
SANOFI101
EPA:SAN (3/29/2023, 7:00:00 PM)+1 (+1%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap252.24B
Analysts76.77
Price Target105.7 (4.65%)
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.69% |
Dividend Growth(5Y)4.16%
DP33.46%
Div Incr Years3
Div Non Decr Years3
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)2.77%
Min EPS beat(2)-0.71%
Max EPS beat(2)6.25%
EPS beat(4)3
Avg EPS beat(4)4.52%
Min EPS beat(4)-0.71%
Max EPS beat(4)8.37%
Revenue beat(2)2
Avg Revenue beat(2)62.5%
Min Revenue beat(2)7.82%
Max Revenue beat(2)117.19%
Revenue beat(4)4
Avg Revenue beat(4)60.48%
Min Revenue beat(4)5.91%
Max Revenue beat(4)117.19%
PT rev (1m)-0.6%
PT rev (3m)1.27%
EPS NQ rev (1m)2.69%
EPS NQ rev (3m)-5.61%
EPS NY rev (1m)-4.06%
EPS NY rev (3m)-4.06%
Revenue NQ rev (1m)0.26%
Revenue NQ rev (3m)-1.47%
Revenue NY rev (1m)-2.26%
Revenue NY rev (3m)-2.26%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 12.24 | ||
| Fwd PE | 12.16 | ||
| P/S | 3.68 | ||
| P/FCF | 30.3 | ||
| P/OCF | 23.96 | ||
| P/B | 3.37 | ||
| P/tB | 77.56 | ||
| EV/EBITDA | 11.4 |
EPS(TTM)8.25
EY8.17%
EPS(NY)8.31
Fwd EY8.22%
FCF(TTM)3.33
FCFY3.3%
OCF(TTM)4.21
OCFY4.17%
SpS27.46
BVpS29.94
TBVpS1.3
PEG (NY)18.35
PEG (5Y)1.48
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.83% | ||
| ROE | 16.66% | ||
| ROIC | 14.93% | ||
| ROICexc | 17.17% | ||
| ROICexgc | 85.41% | ||
| OM | 27.88% | ||
| PM | 18.16% | ||
| GM | 70.25% |
ROICexgc(3y)38.1%
ROICexcg growth 3Y21.31%
ROICexcg growth 5Y10.17%
ROICexc(3y)8.01%
ROICexc growth 3Y11.04%
ROICexc growth 5Y2.97%
OM growth 3Y7.11%
OM growth 5Y2.17%
PM growth 3Y36.08%
PM growth 5Y-4.51%
GM growth 3Y0.81%
GM growth 5Y0.55%
F-Score7
Asset Turnover0.54
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.23 | ||
| Debt/FCF | 2.58 | ||
| Debt/EBITDA | 0.95 | ||
| Cap/Depr | 64.36% | ||
| Profit Quality | 66.84% | ||
| Current Ratio | 1.42 | ||
| Quick Ratio | 1.05 | ||
| Altman-Z | N/A |
F-Score7
WACC7.01%
ROIC/WACC12.18
Cap/Depr(3y)60.69%
Cap/Depr(5y)50.45%
Profit Quality(3y)93.03%
Profit Quality(5y)115.45%
Growth
EPS 1Y25.95%
EPS 3Y11.26%
EPS 5Y8.29%
EPS growth Q2Q23.91%
EPS Next Y0.67%
EPS Next 2Y4.6%
EPS Next 3Y6.55%
EPS Next 5Y7.29%
Revenue growth 1Y16.45%
Revenue growth 3Y6.45%
Revenue growth 5Y4.62%
Revenue growth Q2Q15.77%
Revenue Next Year2%
Revenue Next 2Y3.69%
Revenue Next 3Y4.23%
Revenue Next 5Y4.95%
EBIT growth 1Y31.25%
EBIT growth 3Y14.02%
EBIT growth 5Y6.89%
EBIT Next Year21.59%
EBIT Next 3Y13.17%
EBIT Next 5Y11.87%
FCF growth 1Y-1.82%
FCF growth 3Y11.98%
FCF growth 5Y8.95%
OCF growth 1Y0.04%
OCF growth 3Y10.91%
OCF growth 5Y7.36%
Fundamental Stock Screener Links
Fundamental Stock Screener
Find stocks with similar Fundamental rating on the EuroNext
Best Fundamental Competitors Stock Screener
Find the competitors with the best fundamentals on the EuroNext
Best Valuation Competitors Stock Screener
Find the competitors with the best valuation on the EuroNext
Best Dividend Competitors Stock Screener
Find the competitors with the best dividend on the EuroNext